

MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies

NCT06555237

Status	RECRUITING
Phase	Phase 2
Sponsor	Medical University of Warsaw
Enrollment	40 participants

Key Eligibility Criteria

Inclusion (3)

- patient with diagnosed RASopathy
- patient with diagnosed hypertrophic cardiomyopathy
- signed informed consent

Exclusion (2)

- contraindications to treatment with propranolol (drug hypersensitivity, atrioventricular block, severe bradycardia) disopyramide (drug hypersensitivity, WPW syndrome, atrioventricular block, QT prolongation) trametinib (drug hypersensitivity)
- lack of consent of the child's guardians to participate in the study

Locations (1 total)

Department of Paediatrics, The Medical University of Warsaw, Poland, Warsaw, Poland